PTCT
Ptc Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PTCT
Ptc Therapeutics, Inc.
An established global biopharmaceutical company delivering transformative therapies for people living with rare diseases
500 Warren Corporate Center Drive, Warren, NJ 07059
--
Ptc Therapeutics, Inc., was incorporated as a Delaware corporation on March 31, 1998. PTC Therapeutics, LLC is a biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs for oral use in the post-transcriptional control process. At the same time, the company's research and development plans are aimed at multiple therapeutic areas, and the company is particularly focused on the development and commercialization of treatments for orphan and ultra-orphan disorder diseases. The company's leading product candidate is ataluren, which is used in the treatment of an inherited disease called nonsense mutation gene mutation that occurs during the treatment process.
Earnings Call
Q1/2025
Estimate EPS-0.7
Actual EPS10.04
Estimate Revenue368.26M
Actual Revenue190.00M
Contradictions in PTC Therapeutics' Q1 2025 Call: SUFIANCE Launch, Market Access, and Pricing Strategies Under Scrutiny
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PTCT has released its 2025 Q3 earnings. EPS was reported at 0.2, versus the expected -1.11, beating expectations. The chart below visualizes how PTCT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PTCT has released its 2025 Q3 earnings report, with revenue of 211.01M, reflecting a YoY change of 7.23%, and net profit of 15.90M, showing a YoY change of 114.90%. The Sankey diagram below clearly presents PTCT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
